The Medicaid and CHIP Payment and Access Commission (MACPAC) on Friday (Jan. 27) voted to recommend Congress grant states the ability to impose Medicaid coverage limitations on drugs approved by FDA that lack full evidence of efficacy and for which CMS restricts Medicare coverage as more evidence is gathered on whether the drugs work.